Inovio could take malaria vaccine to human trials next year

08/15/2013 | American City Business Journals

Inovio Pharmaceuticals has announced that its SynCon DNA malaria vaccine elicited lasting antibody and T-cell immune responses in animal studies. A clinical study is expected to begin next year. "We have now generated strong immunology data with our malaria vaccine in nonhuman primates. We are excited to advance toward the very important health care goal of conquering malaria," Inovio President and CEO Dr. J. Joseph Kim said.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park